Skip to main content
  • FDA-Rejected Tx for FCS Proves Mettle in Phase III Trial

    Volanesorsen cut triglyceride levels in patients with familial chylomicronemia syndrome

    Volanesorsen helped to significantly improve triglyceride levels in people with the rare familial chylomicronemia syndrome (FCS), according to the phase III APPROACH trial.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details